Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PRKCD_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PRKCD_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKCD_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKCD_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKCD_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKCD_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004424222 | Liver | HCC | cellular lipid catabolic process | 134/7958 | 214/18723 | 2.07e-09 | 5.79e-08 | 134 |
GO:003461412 | Liver | HCC | cellular response to reactive oxygen species | 102/7958 | 155/18723 | 3.70e-09 | 9.89e-08 | 102 |
GO:003367322 | Liver | HCC | negative regulation of kinase activity | 144/7958 | 237/18723 | 9.76e-09 | 2.45e-07 | 144 |
GO:003253522 | Liver | HCC | regulation of cellular component size | 217/7958 | 383/18723 | 1.28e-08 | 3.14e-07 | 217 |
GO:000193322 | Liver | HCC | negative regulation of protein phosphorylation | 196/7958 | 342/18723 | 1.95e-08 | 4.63e-07 | 196 |
GO:003227122 | Liver | HCC | regulation of protein polymerization | 141/7958 | 233/18723 | 2.00e-08 | 4.72e-07 | 141 |
GO:005117011 | Liver | HCC | import into nucleus | 102/7958 | 159/18723 | 2.78e-08 | 6.39e-07 | 102 |
GO:003297022 | Liver | HCC | regulation of actin filament-based process | 222/7958 | 397/18723 | 3.81e-08 | 8.30e-07 | 222 |
GO:00066066 | Liver | HCC | protein import into nucleus | 99/7958 | 155/18723 | 6.12e-08 | 1.28e-06 | 99 |
GO:00082862 | Liver | HCC | insulin receptor signaling pathway | 78/7958 | 116/18723 | 6.15e-08 | 1.29e-06 | 78 |
GO:003295622 | Liver | HCC | regulation of actin cytoskeleton organization | 202/7958 | 358/18723 | 6.18e-08 | 1.29e-06 | 202 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
GO:003133312 | Liver | HCC | negative regulation of protein-containing complex assembly | 91/7958 | 141/18723 | 1.01e-07 | 1.98e-06 | 91 |
GO:000647021 | Liver | HCC | protein dephosphorylation | 162/7958 | 281/18723 | 1.91e-07 | 3.46e-06 | 162 |
GO:000815422 | Liver | HCC | actin polymerization or depolymerization | 130/7958 | 218/18723 | 2.31e-07 | 4.14e-06 | 130 |
GO:003004122 | Liver | HCC | actin filament polymerization | 116/7958 | 191/18723 | 2.66e-07 | 4.68e-06 | 116 |
GO:003530412 | Liver | HCC | regulation of protein dephosphorylation | 62/7958 | 90/18723 | 3.66e-07 | 6.22e-06 | 62 |
GO:004682411 | Liver | HCC | positive regulation of nucleocytoplasmic transport | 46/7958 | 62/18723 | 4.01e-07 | 6.77e-06 | 46 |
GO:000646912 | Liver | HCC | negative regulation of protein kinase activity | 126/7958 | 212/18723 | 4.55e-07 | 7.49e-06 | 126 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCD | SNV | Missense_Mutation | novel | c.1115N>T | p.Gly372Val | p.G372V | Q05655 | protein_coding | deleterious(0.01) | benign(0.342) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PRKCD | SNV | Missense_Mutation | novel | c.548A>T | p.Asn183Ile | p.N183I | Q05655 | protein_coding | deleterious(0.03) | probably_damaging(0.985) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCD | SNV | Missense_Mutation | | c.1573N>A | p.Tyr525Asn | p.Y525N | Q05655 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PRKCD | SNV | Missense_Mutation | rs781980599 | c.277N>A | p.Glu93Lys | p.E93K | Q05655 | protein_coding | deleterious(0.02) | benign(0.407) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
PRKCD | SNV | Missense_Mutation | novel | c.609N>C | p.Lys203Asn | p.K203N | Q05655 | protein_coding | tolerated(0.21) | possibly_damaging(0.811) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PRKCD | insertion | Frame_Shift_Ins | novel | c.1528_1529insAGGAGAAGCAGAGGCTGCTC | p.Gly510GlufsTer21 | p.G510Efs*21 | Q05655 | protein_coding | | | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCD | insertion | Frame_Shift_Ins | novel | c.1989_1990insA | p.Ser664IlefsTer22 | p.S664Ifs*22 | Q05655 | protein_coding | | | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCD | insertion | Nonsense_Mutation | novel | c.1990_1991insTTTAAAATATAAGTTCAGGCCGGGCACAGTGGC | p.Ser664delinsPheTerAsnIleSerSerGlyArgAlaGlnTrpPro | p.S664delinsF*NISSGRAQWP | Q05655 | protein_coding | | | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCD | SNV | Missense_Mutation | rs149165175 | c.604G>A | p.Asp202Asn | p.D202N | Q05655 | protein_coding | tolerated(0.07) | benign(0.105) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKCD | SNV | Missense_Mutation | rs782258819 | c.422N>T | p.Thr141Met | p.T141M | Q05655 | protein_coding | tolerated(0.12) | benign(0.107) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | TAE-684 | TAE-684 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | [3H]-PHORBOL 12,13-DIBUTYRATE | CHEMBL27768 | 24794745 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | GO-6976 | GO-6976 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | ETHANOL | ALCOHOL | 1744136 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL565612 | SOTRASTAURIN | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | 178101947 | RUBOXISTAURIN | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | ENOXOLONE | ENOXOLONE | 24461294 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL574737 | UCN-01 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | KAI-9803 | DELCASERTIB | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL608533 | MIDOSTAURIN | |